The potential reason that the results of our study differ from those of previous research is that the hypoglycemic effect of insulin plays a greater role than its proliferative effect in these type 2 diabetes patients with CRC, whose glucose was poorly managed, as reflected by the lower use of most kinds of diabetes medicines. This evidence concerns the gene INS and colorectal carcinoma.